Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes
Inflammation expert opinions5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain
Prof. Raffaele de Caterina explains why CANTOS is an important trial. It is the first trial showing that an anti-inflammatory drug can affect important CV outcomes and thus may be a convenient therapy in addition to current treatment strategies.
Video navigation menu
- Why is CANTOS an important trial? 01:09
- Dose-response evaluation not standard in phase 3 trials 02:24
- By analysing the results, choose which patient benefits most 03:05
- Potential mechanism of action canakinumab 04:18
- Breakthrough therapy in addition to current treatment strategies 05:19
The CANTOS trial is the first in a series of trials that test the hypothesis that inhibiting inflammation can lower residual CV risk. The results of this trial indeed confirm this hypothesis, suggesting that from now on, targeting inflammation may need to be considered in patients on lipid-lowering therapy with residual inflammatory CV risk.
These inflammation expert opinion videos are aimed to provide guidance and perspectives on the implications of the CANTOS trial and other trials addressing inflammation in CVD. These expert views may help translate scientific findings to future clinical practice, by improving personalized CV risk management.
This recording was developed under auspices of PACE-cme.
The views expressed in this recording are those of the presenter and do not necessarily reflect the views of PACE-cme.
Prof. Raffaele De Caterina, MD, Professor of Cardiology, G. d’Annunzio University in Chieti, Italy
Funding to produce this expert opinion was provided by an unrestricted educational grant from Novartis.